Clinical Trials
16 trialsNCT03756298 2026-04-23
Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Center, Korea
Phase 2 Active not recruiting
NCT07327021 2026-01-08
NOGA
Tel-Aviv Sourasky Medical Center
Phase 2 Recruiting
NCT06817525 2025-12-05
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
Henan Cancer Hospital
Phase 2 Recruiting
NCT07256964 2025-12-02
Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT05722795 2025-07-09
I-CONIC
Vastra Gotaland Region
Phase NA Recruiting
NCT06819319 2025-06-23
SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT03168880 2025-04-09
TNBC
Tata Memorial Hospital
Phase 3 Active not recruiting
NCT06880029 2025-03-19
CIRCADIAN
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
Phase 1/2 Recruiting
NCT05475678 2025-01-23
Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
Henan Cancer Hospital
Phase 2 Recruiting
NCT04664972 2024-09-20
Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC
Henan Cancer Hospital
Phase 2 Completed
NCT06078670 2023-10-12
PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors
Fujian Cancer Hospital
Phase 1/2 Not yet recruiting
NCT05957939 2023-07-24
Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial
Ministry of Health, Saudi Arabia
Phase 1 Unknown
NCT05680662 2023-01-11
The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism
Ministry of Health, Saudi Arabia
Phase EARLY_PHASE1 Unknown
NCT04142931 2021-03-24
Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
Sheba Medical Center
Phase 1 Unknown
NCT04213898 2019-12-30
SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
Henan Cancer Hospital
Phase 1/2 Unknown
NCT01939418 2017-10-03
Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
National Cancer Center, Korea
Phase 1/2 Terminated